| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $77.1M | +83.0% |
| SG&A Expense | $34.5M | +34.0% |
| Operating Income | -$111.6M | -34.4% |
| Net Income | -$94.3M | -29.3% |
| EPS (Basic) | -$1.68 | +30.6% |
| EPS (Diluted) | -$1.68 | +30.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $59.8M | -65.9% |
| Short-term Investments | $268.3M | +277.9% |
| Current Assets | $334.6M | +33.4% |
| Total Assets | $342.4M | +34.4% |
| Current Liabilities | $19.1M | +65.6% |
| Total Liabilities | $23.1M | +100.0% |
| Stockholders' Equity | $319.3M | +31.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$81.2M | -18.7% |
| Capital Expenditures | $325K | +1200.0% |
| Investing Cash Flow | -$191.9M | -242.1% |
| Financing Cash Flow | $157.2M | +77.8% |
| Free Cash Flow | -$81.5M | -19.1% |